|
|
|
|
Radiotracer imaging (RTI) of the nigrostriatal dopaminergic system is a widely used but controversial biomarker in Parkinson disease (PD). Here the authors review the concepts of biomarker development and the evidence to support the use of four radiotracers as biomarkers in PD. [18F]fluorodopa PET, (+)-[11C]dihydrotetrabenazine PET, [123I]B-CIT SPECT, and [18F]fluorodeoxyglucose PET. |
|